SELPLG and plasma cell myeloma: Therapeutically, PSGL-1 mAb can repolarize M2 macrophages to the M1-like phenotype and induce an inflammatory microenvironment, thus enhancing anti-tumor activity in myeloma cells and humanized mouse models [137,140].